Neurocrine Biosciences (NBIX) Revenue Growth (5y) (2016 - 2026)
Neurocrine Biosciences (NBIX) Revenue Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - |
| 10 | Alkermes | 8.17 Bn | 7.51 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.12% |
| Mar 31, 2026 | 28.05% |
| Dec 31, 2025 | 26.58% |
| Sep 30, 2025 | 25.19% |
| Jun 30, 2025 | 17.85% |
| Mar 31, 2025 | 19.28% |
| Dec 31, 2024 | 20.79% |
| Sep 30, 2024 | 22.87% |
| Jun 30, 2024 | 26.32% |
| Mar 31, 2024 | 30.07% |
| Dec 31, 2023 | 31.41% |
| Sep 30, 2023 | 26.87% |
| Jun 30, 2023 | 36.11% |
| Mar 31, 2023 | 42.68% |
| Dec 31, 2022 | 34.24% |
| Sep 30, 2022 | 44.88% |
| Jun 30, 2022 | 25.85% |
| Mar 31, 2021 | 73.61% |
| Mar 31, 2020 | 64.36% |
| Dec 31, 2018 | 182.56% |